BioNTech (BNTX) Q3 2025 earnings summary

Executive summary

• Advanced late-stage oncology pipeline with pumitamig (PD-L1 VEGF-A bispecific) and mRNA cancer immunotherapies, progressing multiple registrational and signal-seeking trials across lung, breast, colorectal, and gastric cancers.

• Expanded mRNA cancer immunotherapy programs (FixVac, iNeST) with recent Phase 2 data in melanoma and colorectal cancer guiding future development.

• Launched and received regulatory approvals for a variant-adapted COVID-19 vaccine in major markets, maintaining commercial leadership.

• Maintained a strong financial position with €16.7 billion in cash, cash equivalents, and securities, supported by BMS partnership payments.

Financial highlights

• Q3 2025 revenues reached €1,519 million, up from €1,245 million year-over-year, mainly due to BMS collaboration income; nine-month revenues were €1,963 million.

• Q3 2025 net loss was €29 million, compared to net income of €198 million in Q3 2024; nine-month net loss was €831 million, improved from €925 million loss prior year.

• R&D expenses for Q3 2025 were €565 million, slightly up year-over-year; nine-month R&D expenses were €1,600 million.

• Basic and diluted loss per share for Q3 2025 was €0.12, versus €0.82 and €0.81 earnings per share in Q3 2024.

• Cash and securities totaled €16.7 billion at quarter-end, including BMS upfront payments.

Outlook and guidance

• Full-year 2025 revenue guidance raised to €2.6–2.8 billion, reflecting BMS collaboration revenue.

• R&D expense guidance lowered to €2.0–2.2 billion, SG&A to €550–650 million, and capital expenditures to €200–250 million.

• No positive net income expected for 2025 as investments continue in oncology transition.

• Guidance assumes stable COVID-19 vaccine pricing and market share, with inventory write-downs estimated at 15% of gross profit from vaccine sales in Pfizer's territory.